Quick Answer
CHAMPIONS ONCOLOGY, INC. reported Total Revenue of $56.94 million for fiscal year 2025.
CHAMPIONS ONCOLOGY, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | $56.94M +13.5% |
$50.16M -6.9% |
$53.87M +9.7% |
$49.11M +19.7% |
$41.04M +27.8% |
$32.12M +18.7% |
| Revenue (ASC 606) | $56.94M +13.5% |
$50.16M -6.9% |
$53.87M +9.7% |
$49.11M +19.7% |
$41.04M +27.8% |
$32.12M +18.7% |
| Net Income | $4.70M +164.6% |
-$7.28M -36.4% |
-$5.33M -1073.5% |
$548.0K +51.4% |
$362.0K +117.3% |
-$2.09M -1735.2% |
| Diluted EPS | $0.33 +161.1% |
-$0.54 -38.5% |
-$0.39 -1075.0% |
$0.04 +100.0% |
$0.02 +111.1% |
-$0.18 -1900.0% |
| Total Assets | $32.34M +23.8% |
$26.13M -23.8% |
$34.31M -3.0% |
$35.38M +28.2% |
$27.59M +33.0% |
$20.75M +84.2% |
| Cash and Equivalents | — | — | — | — | — | — |
| Stockholders Equity | $3.77M +298.2% |
-$1.90M -141.0% |
$4.64M -49.0% |
$9.10M +12.5% |
$8.09M +58.6% |
$5.10M +138.6% |
| R&D Expense | $6.83M -28.5% |
$9.54M -17.3% |
$11.54M +23.2% |
$9.37M +30.3% |
$7.20M +22.9% |
$5.85M +22.0% |
| Operating Income | $4.55M +161.9% |
-$7.36M -40.0% |
-$5.26M -965.9% |
$607.0K +65.8% |
$366.0K +119.1% |
-$1.92M -811.5% |
| Shares Outstanding | 13.78M +1.3% |
13.59M +0.4% |
13.54M +0.2% |
13.52M +0.8% |
13.41M +5.4% |
12.73M +9.5% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | January 31, 2026 | $16.56M | -2.8% | +10.1% |
| Revenue (ASC 606) | January 31, 2026 | $16.56M | -2.8% | +10.1% |
| Net Income | January 31, 2026 | -$279.0K | -106.2% | -204.1% |
| Diluted EPS | January 31, 2026 | -$0.02 | -106.5% | -200.0% |
| Total Assets | January 31, 2026 | $28.45M | -7.1% | -5.7% |
| Cash and Equivalents | January 31, 2026 | $7.13M | +122.6% | -16.3% |
| Stockholders Equity | January 31, 2026 | $4.28M | -21.7% | +2.7% |
| R&D Expense | January 31, 2026 | $2.27M | +32.1% | -13.2% |
| Operating Income | January 31, 2026 | -$276.0K | -106.1% | -249.2% |
| Shares Outstanding | January 31, 2026 | 13.89M | +1.3% | +0.0% |
- CHAMPIONS ONCOLOGY, INC. reported Total Revenue of $56.94 million for fiscal year 2025.
- CHAMPIONS ONCOLOGY, INC. showed an increase of +13.5% in Total Revenue compared to the prior fiscal year.
- CHAMPIONS ONCOLOGY, INC. reported Revenue (ASC 606) of $56.94 million for fiscal year 2025.
- CHAMPIONS ONCOLOGY, INC. showed an increase of +13.5% in Revenue (ASC 606) compared to the prior fiscal year.
- CHAMPIONS ONCOLOGY, INC. reported Net Income of $4.70 million for fiscal year 2025.
- CHAMPIONS ONCOLOGY, INC. showed an increase of +164.6% in Net Income compared to the prior fiscal year.
- CHAMPIONS ONCOLOGY, INC. reported Diluted EPS of $0.33 per share for fiscal year 2025.
- CHAMPIONS ONCOLOGY, INC. showed an increase of +161.1% in Diluted EPS compared to the prior fiscal year.
- CHAMPIONS ONCOLOGY, INC. reported Total Assets of $32.34 million for fiscal year 2025.
- CHAMPIONS ONCOLOGY, INC. showed an increase of +23.8% in Total Assets compared to the prior fiscal year.
- CHAMPIONS ONCOLOGY, INC. reported Cash and Equivalents of $3.24 million for fiscal year 2019.
- CHAMPIONS ONCOLOGY, INC. showed an increase of +278.2% in Cash and Equivalents compared to the prior fiscal year.
- CHAMPIONS ONCOLOGY, INC. reported Stockholders Equity of $3.77 million for fiscal year 2025.
- CHAMPIONS ONCOLOGY, INC. showed an increase of +298.2% in Stockholders Equity compared to the prior fiscal year.
- CHAMPIONS ONCOLOGY, INC. reported R&D Expense of $6.83 million for fiscal year 2025.
- CHAMPIONS ONCOLOGY, INC. showed a decrease of -28.5% in R&D Expense compared to the prior fiscal year.
- CHAMPIONS ONCOLOGY, INC. reported Operating Income of $4.55 million for fiscal year 2025.
- CHAMPIONS ONCOLOGY, INC. showed an increase of +161.9% in Operating Income compared to the prior fiscal year.
- CHAMPIONS ONCOLOGY, INC. reported Shares Outstanding of 13.78 million shares for fiscal year 2025.
- CHAMPIONS ONCOLOGY, INC. showed an increase of +1.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: